Magurol

Doxazosin, the active ingredient in Magurol, is an alpha‑1 adrenergic blocker presented as a tablet for oral use. It is prescribed to lower high blood pressure and to relieve urinary obstruction caused by an enlarged prostate in adult patients.

GNH USA supplies Magurol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets and providing reliable logistics for timely delivery.

Doxazosin is used in conditions that involve alpha‑1 receptor‑mediated vascular tone or smooth‑muscle contraction.

- Hypertension: reduces systolic and diastolic blood pressure by causing vasodilation. - Benign prostatic hyperplasia (BPH): improves urinary flow by relaxing smooth muscle in the prostate and bladder neck. - Peripheral vascular resistance reduction: assists in overall management of elevated blood pressure.

Common side effects are generally mild and may resolve with continued therapy.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or weakness - Nasal congestion - Peripheral edema - Nausea or abdominal discomfort

Serious or Rare Side Effects: - Severe hypotension or syncope - Acute heart failure exacerbation - Priapism (prolonged erection) - Sudden severe liver injury (rare) - Allergic reactions such as rash or angioedema

Before initiating therapy, consider the following safety measures.

- Blood pressure monitoring: check baseline and periodic readings. - Renal function assessment: adjust use in significant impairment. - Hepatic impairment: use with caution and monitor liver enzymes. - Concomitant antihypertensives: avoid excessive blood pressure drop. - Discontinuation: taper rather than abrupt stop to prevent rebound hypertension. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Doxazosin may interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Other alpha‑blockers (e.g., prazosin, terazosin): additive hypotensive effect. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increased plasma concentrations. - Phosphodiesterase‑5 inhibitors (e.g., sildenafil, tadalafil): risk of severe hypotension.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance orthostatic hypotension. - ACE inhibitors or ARBs: additive blood pressure lowering. - NSAIDs: may blunt antihypertensive response. - Calcium channel blockers: possible increased effect on blood pressure. - Tricyclic antidepressants: may potentiate hypotensive episodes.